SecSonar.com

Axsome Therapeutics, Inc. (AXSM)

Axsome Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Axsome Therapeutics, Inc. (AXSM) is a Biotechnology company based in US with a market capitalization of $12B. Revenue grew 65.5% year-over-year and free cash flow was negative at -$93.9M. This page tracks AXSM's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 712 employees · IPO Nov 19, 2015

Valuation

Valuation & price

$227.72 · as of May 17, 2026 · -10.8% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

136.08

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$254$177$100Jul 25Dec 25Jul 26Jul 7, 25$107.50Jul 9, 25$112.35Jul 11, 25$108.98Jul 15, 25$110.12Jul 17, 25$112.24Jul 21, 25$109.68Jul 23, 25$106.36Jul 25, 25$100.83Jul 29, 25$100.41Jul 31, 25$101.38Aug 4, 25$106.54Aug 6, 25$103.26Aug 11, 25$103.96Aug 13, 25$109.39Aug 15, 25$109.22Aug 19, 25$111.29Aug 21, 25$117.14Aug 25, 25$116.31Aug 27, 25$121.86Aug 29, 25$121.28Sep 3, 25$122.00Sep 5, 25$125.17Sep 9, 25$125.68Sep 11, 25$122.96Sep 16, 25$114.10Sep 18, 25$118.63Sep 22, 25$117.49Sep 24, 25$118.77Sep 26, 25$116.76Sep 30, 25$121.45Oct 2, 25$119.94Oct 6, 25$119.94Oct 8, 25$118.71Oct 10, 25$121.71Oct 14, 25$123.52Oct 16, 25$125.00Oct 21, 25$131.39Oct 23, 25$127.06Oct 27, 25$134.68Oct 29, 25$133.33Oct 31, 25$134.99Nov 4, 25$134.93Nov 6, 25$139.41Nov 10, 25$137.80Nov 12, 25$140.86Nov 14, 25$139.69Nov 18, 25$147.48Nov 20, 25$143.31Nov 25, 25$150.36Nov 28, 25$151.50Dec 2, 25$142.09Dec 4, 25$148.04Dec 8, 25$147.56Dec 10, 25$149.26Dec 12, 25$148.17Dec 16, 25$146.87Dec 18, 25$147.00Dec 22, 25$154.70Dec 24, 25$153.64Dec 29, 25$150.68Jan 2, 26$178.69Jan 6, 26$171.88Jan 8, 26$167.55Jan 12, 26$176.82Jan 14, 26$177.01Jan 16, 26$177.27Jan 21, 26$189.10Jan 23, 26$185.96Jan 27, 26$188.02Jan 29, 26$185.27Feb 2, 26$185.88Feb 4, 26$185.54Feb 9, 26$183.22Feb 11, 26$186.21Feb 13, 26$181.21Feb 18, 26$184.74Feb 20, 26$183.72Feb 24, 26$169.95Feb 26, 26$163.19Mar 2, 26$166.38Mar 4, 26$164.08Mar 6, 26$162.33Mar 10, 26$166.34Mar 12, 26$154.12Mar 17, 26$161.17Mar 19, 26$158.88Mar 23, 26$156.84Mar 25, 26$161.78Mar 27, 26$156.35Mar 31, 26$169.02Apr 2, 26$168.51Apr 7, 26$168.74Apr 9, 26$178.90Apr 13, 26$178.33Apr 15, 26$184.18Apr 17, 26$188.99Apr 22, 26$186.42Apr 24, 26$185.96Apr 28, 26$185.00Apr 30, 26$207.75May 4, 26$223.70May 6, 26$222.63May 8, 26$217.38May 12, 26$224.03May 14, 26$232.27May 18, 26$227.40May 20, 26$230.62May 22, 26$235.97May 28, 26$232.83Jun 1, 26$230.25Jun 3, 26$233.49Jun 5, 26$232.32Jun 9, 26$245.64Jun 11, 26$253.77Jun 15, 26$253.40Jun 17, 26$252.16Jun 22, 26$247.85Jun 24, 26$237.92Jun 26, 26$241.67Jul 2, 26$244.31
$100.3952-week range$255.17
Loading valuation history…

Fundamentals

Key fundamentals

$12B

Market cap

65.5%

Revenue growth (YoY)

92.6%

Gross margin

-$93.9M

Free cash flow (USD)

-$81.6M

Net debt

Net cash position

3.8%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$0.00FY 2019$0.00FY 2020$0.00FY 2021$0.00FY 2022$50.0MFY 2023$270.6MFY 2024$385.7MFY 2025$638.5M
$0$638.5M

Free cash flow by year

2016 → 2025

FY 2016$-21.4MFY 2017$-26.5MFY 2018$-30.1MFY 2019$-46.4MFY 2020$-78.5MFY 2021$-108.5MFY 2022$-117.2MFY 2023$-145.7MFY 2024$-128.7MFY 2025$-93.9M
-$21.4M-$93.9M

Gross margin by year

2022 → 2025

FY 202289.6%FY 202390.4%FY 202491.4%FY 202592.6%
89.6%92.6%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

9

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 4, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $11.9M · 10b5-1 PlanTABUTEAU HERRIOT · Director, Chief Executive Officer, 10% Owner · $11.9MJul 1, 2026Filing
  • Insider sellInsider Sell $142K · 10b5-1 PlanJEFFS ROGER · Director · $141.7KJun 11, 2026Filing
  • Insider sellInsider Sell $160K · 10b5-1 PlanColeman Mark · Director · $160.1KJun 10, 2026Filing
  • Insider sellInsider Sell $145K · 10b5-1 PlanMahony Susan · Director · $145KJun 10, 2026Filing
  • Insider sellInsider Sell $7.9M · 10b5-1 PlanPizzie Nick · Chief Financial Officer · $7.9MJun 9, 2026Filing
  • Insider sellInsider Sell $12.0M · 10b5-1 PlanTABUTEAU HERRIOT · Director, Chief Executive Officer, 10% Owner · $12MJun 9, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 9, 2026Filing
  • 8-K eventExecutive Severance Plan EstablishedJun 9, 2026Filing
  • 8-K eventPatent Litigation SettlementJun 3, 2026Filing
  • Insider sellInsider Sell $4.0M · 10b5-1 PlanColeman Mark · Director · $4MJun 2, 2026Filing

Questions

Frequently asked questions

What is Axsome Therapeutics, Inc.'s market cap?

Axsome Therapeutics, Inc. (AXSM) has a market capitalization of $12B.

What is AXSM's P/E ratio?

A meaningful P/E ratio is not available for AXSM — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is AXSM's price-to-book (P/B) ratio?

AXSM trades at 136.08 times book value per share.

Are insiders buying AXSM stock?

SEC Form 4 filings show no open-market insider buys at Axsome Therapeutics, Inc. in the last 90 days (9 sells).

Same arena

Related companies in Biotechnology

MDGL

Madrigal Pharmaceuticals, Inc.

$11.5B

IONS

Ionis Pharmaceuticals, Inc.

$12.9B

EXEL

Exelixis, Inc.

$12.9B

ARWR

Arrowhead Pharmaceuticals, Inc.

$10.9B

BBIO

BridgeBio Pharma, Inc.

$13.2B

ASND

Ascendis Pharma A/S

$13.7B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.